Lung, Phase I-II
Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Abhijit Patel, MD, PhD
- Allison Campbell, MD, PhD
- Anca Bulgaru, MD
- Andrea Brennan
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Bruce A. McGibbon, MD
- Christin A. Knowlton, MD, MA
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Francesca Montanari, MD
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- James Laird, MD
- James E. Hansen, MD, MS
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jeremy Kortmansky, MD
- Justin Persico, MD
- Kenneth B. Roberts, MD
- Kimberly L. Johung, MD, PhD
- Kristen Hoxie
- Larisa Fleysher
- M. Sung Lee, MD
- Meena S. Moran, MD
- Melissa Rasar Young, MD, PhD
- Michael Cohenuram, MD
- Nadine Housri, MD
- Neal Fischbach, MD
- Robert Legare, MD
- Roy S. Herbst, MD, PhD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Thomas Hayman, MD, PhD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yi An, MD
- Last Updated01/05/2025
- Study HIC#2000025868